 | Up a level |
Lim, Sun Min and Tan, Jiunn-Liang and Dias, Josiane Mourao and Voon, Pei Jye and How, Soon Hin and Zhou, Xiangdong and Xiong, Hailin and Massuti, Bartomeu and Medley, Louise C. and Nagasaka, Misako and Vicente, David and Girard, Nicolas and Rittmeyer, Achim and Botesteanu, Dana-Adriana and Alhadab, Ali and Mahoney, Janine M. and Zhang, Jie and Bauml, Joshua Michael and Baig, Mahadi and Scott, Susan Combs (2024) Subcutaneous amivantamab and lazertinib as first-line treatment in patients with <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study. Journal of Clinical Oncology, 42 (17_SUP). LBA8612. ISSN 0732-183X, DOI https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8612.
